These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1194 related articles for article (PubMed ID: 31862149)

  • 21. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
    Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
    J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
    Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS
    Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
    Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
    BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
    Forbes AK; Suckling RJ; Hinton W; Feher MD; Banerjee D; Cole NI; de Lusignan S; Swift PA
    Diabetes Obes Metab; 2023 Aug; 25(8):2310-2330. PubMed ID: 37202870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
    Tangri N; Rastogi A; Nekeman-Nan C; Hong LS; Ozaki A; Franzén S; Sofue T
    Adv Ther; 2024 Mar; 41(3):1151-1167. PubMed ID: 38240949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.
    Chan GC; Ng JK; Chow KM; Szeto CC
    Diabetes Res Clin Pract; 2023 Jan; 195():110200. PubMed ID: 36481225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
    Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
    Apperloo EM; Neuen BL; Fletcher RA; Jongs N; Anker SD; Bhatt DL; Butler J; Cherney DZI; Herrington WG; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Sabatine MS; Solomon SD; Staplin N; Szarek M; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F; Heerspink HJL
    Lancet Diabetes Endocrinol; 2024 Aug; 12(8):545-557. PubMed ID: 38991584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Suzuki Y; Kaneko H; Okada A; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Nangaku M; Yasunaga H; Komuro I
    Kidney Int; 2022 Nov; 102(5):1147-1153. PubMed ID: 35961884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cao H; Rao X; Jia J; Yan T; Li D
    Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.